Akademik Veri Yönetim Sistemi
TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.29, sa.1, ss.162-168, 2009 (SCI-Expanded)
Objective: In this retrospective study, the clinical features, treatment modalities and survival durations of 111 patients with chronic myeloproliferative disorders (MPDs) were analyzed. Material and Methods: The medical records of 111 MPD patients including 58 patients with polycythemia vera (PV), 32 with essential thrombocythemia (ET), and 21 with idiopathic myelofibrosis (IMF) who presented to our center between 1987-2006 were evaluated. Results: Among all of the patients, 57 were female and 54 were male (female/male ratio, 1.1). The median age at the time of diagnosis was 61 years (range, 28-81 years). Thrombotic events were more common than bleeding in patients with PV (thrombotic/hemorrhagic events: 34/16) and ET (thrombotic/hemorrhagic events: 21/11) whereas bleeding was slightly more common than thrombotic events in patients with IMF (thrombotic/hemorrhagic events: 4/5). Arterial thrombotic events predominated over venous events and involved primarily cerebral and coronary arteries. The majority of bleeding manifestations affected the skin, mucous membranes, and the gastrointestinal system. Kaplan-Meier curves showed that mean survival time was 21.3 +/- 3.6 years (1-29) in PV patients and 12.7 +/- 0.3 years (1-13) in ET patients while IMF patients had a mean survival time of 7.4 +/- 1.5 years (0.5-12). Survival was shortened with advanced age (p < 0.05), anemia (p < 0.05) and male gender (p > 0.05). Conclusion: MPDs share many overlapping clinical and laboratory features but exhibit different survival rates being highest for PV and lowest for IMF. The relatively high frequency of thromboembolic complications in this study cohort emphasizes the importance of using an antithrombotic preventive strategy in MPD patients.